Pyr-Apelin-13 treatment has been reported to downregulate Ang II and endothelin-1 and could therefore attenuate RV hypertrophy and diastolic dysfunction in rats with PAH [27]. This evidence concerns the gene APLN and pulmonary arterial hypertension.